2022 World Conference on Lung Cancer (ePosters)-EP08.01-020. Phase 2 Platform Trial of Anti-TIGIT GSK'859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)

EP08.01-020. Phase 2 Platform Trial of Anti-TIGIT GSK'859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)

Pdf Summary

Summary Not Available

Asset Subtitle

David Spigel

Meta Tag

Speaker David Spigel

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy